Loading...
Glaukos Corporation reported a significant increase in net sales for Q2 2021, with a 147% increase to $78.1 million compared to $31.6 million in Q2 2020. The company's gross margin also improved to approximately 77%, and non-GAAP gross margin reached approximately 84%.
Net sales increased by 147% to $78.1 million compared to Q2 2020.
Glaucoma net sales reached $62.7 million.
Corneal Health net sales totaled $15.4 million.
Gross margin was approximately 77%, and non-GAAP gross margin was approximately 84%.
The company expects 2021 net sales to be in the range of $285 million to $290 million.